Given the importance of CD4+Th1 cells in anti-viral responses, our findings have provided a potential mechanism to explain the existing clinical observations showing worse COVID-19 outcomes in patients with type 2 diabetes who only received a single dose of BNT162b2 (30–33). This evidence concerns the gene CD4 and type 2 diabetes mellitus.